بدائل البحث:
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
shape decrease » shape increases (توسيع البحث), small decrease (توسيع البحث), showed decreased (توسيع البحث)
step decrease » sizes decrease (توسيع البحث), teer decrease (توسيع البحث), we decrease (توسيع البحث)
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
shape decrease » shape increases (توسيع البحث), small decrease (توسيع البحث), showed decreased (توسيع البحث)
step decrease » sizes decrease (توسيع البحث), teer decrease (توسيع البحث), we decrease (توسيع البحث)
-
1521
-
1522
-
1523
-
1524
-
1525
-
1526
-
1527
-
1528
-
1529
-
1530
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
منشور في 2024الموضوعات: -
1531
-
1532
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1533
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1534
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1535
-
1536
-
1537
-
1538
-
1539
-
1540